OncoMatch/Clinical Trials/NCT05878028
L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC
Is NCT05878028 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies L-TIL, Tislelizumab, Docetaxel for non-small cell lung cancer.
Treatment: L-TIL, Tislelizumab, Docetaxel — The goal of this observational study is to test in advanced non-small cell lung cancer patients with negative driver gene. For these patients, PD1 antibody therapy combined with chemotherapy was the preferred regimen. However, there is no standard regimen for the patients who refractory from the first-line PD1 inhibitor based therapy. The main questions they aim to answer are: 1.The efficacy of Liquid Tumor Infiltrating Lymphocytes (L-TIL) plus Tislelizumab and Docetaxel for patients failure from first line chemotherapy and PD1 inhibitor therapy. 2. The safety of L-TIL plus Tislelizumab and Docetaxel as second line therapy. All participants will receive four cycles of Docetaxel chemotherapy, six cycles of L-TIL cells infusion and one year of Tislelizumab treatment except for disease progression, intolerable toxicity, withdrawal informed consent, death and so on.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: MET wild-type
Required: RET wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy
Failure from anti-PD-1 antibody treatment, including treatment ineffective or effective for a period then progress.
Lab requirements
Blood counts
Enough organ functions well.
Kidney function
Enough organ functions well.
Liver function
Enough organ functions well.
Enough organ functions well.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify